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Abstract 
New drugs are needed for relapsed acute lymphoblastic leukemia and preclinical evaluation 
of the MEK inhibitor, selumetinib, has shown excellent activity in those with RAS pathway 
mutations. The proapoptotic protein, BIM is pivotal in the induction of cell death by both 
selumetinib and glucocorticoids, suggesting the potential for synergy. Thus, combination 
indices for dexamethasone and selumetinib were determined in RAS pathway mutated acute 
lymphoblastic leukemia primagraft cells in vitro and were indicative of strong synergism (CI 
<0.2; n=5). Associated pharmacodynamic assays were consistent with the hypothesis that the 
drug combination enhanced BIM upregulation over single drug alone. Dosing of 
dexamethasone and selumetinib singly, and in combination in mice engrafted with primary 
derived RAS pathway mutated leukemia cells, resulted in a marked reduction in spleen size 
which was significantly greater with the drug combination. Assessment of the central nervous 
system leukaemia burden showed a significant reduction in drug treated mice, with no 
detectable leukemia in those treated with the drug combination. These data suggest that a 
selumetinib-dexamethasone combination may be highly effective in RAS pathway mutated 
acute lymphoblastic leukemia and an international phase I/II clinical trial of dexamethasone 
and selumetinib (Seludex trial) is underway for children with multiple relapsed/refractory 
disease. 
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Introduction 
Progress in the treatment of childhood acute lymphoblastic leukaemia has been exceptional 
and using contemporary regimens, sustained remission is achievable in almost 90% of 
children 1, 2. However, the outcome of children who relapse is much poorer and remains a 
frequent cause of death in children with cancer 3-5. Since further intensification with 
traditional agents is often associated with significant toxicity and limited success, new 
therapies are clearly needed. One promising avenue that may deliver novel drugs comes from 
our previous work showing that mutation in genes which activate the Ras/Raf/Mek/Erk 
pathway such as NRAS, KRAS, FLT3, and PTPN11 are highly prevalent in relapsed ALL and 
importantly, mutated ALL cells are differentially sensitive to the MEK inhibitor, selumetinib 
(AZD6244, ARRY-142886)6-8. In contrast, RAS pathway wildtype ALL cells were 
insensitive to MEK inhibition, both in vitro and in vivo6. In the IBFMREZ2002 clinical trial 
for relapsed ALL, RAS pathway mutations were associated with high risk features such as 
early relapse, central nervous system (CNS) disease and chemo-resistance and a poorer 
overall survival was seen in patients with KRAS mutations 6. In the UKALLR3 trial, a poorer 
survival was seen in children with NRAS mutations 7. Thus, this genetic subtype of relapsed 
ALL clearly warrants exploratory therapies. 
 
The Ras/Raf/Mek/Erk cascade regulates diverse cellular functions, including cell 
proliferation, survival, differentiation, angiogenesis and migration and is deregulated in 
numerous cancers, including ALL 9-13. Classic activation is initiated by ligand binding to 
receptor tyrosine kinases at the cell surface and via Ras, then Raf activates MEK1/2 which 
has restricted substrate specify for extracellular signal–regulated kinase 1 and 2 (Erk).  ERK 
is a potent kinase with over 200 nuclear and cytoplasmic substrates including transcription 
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factors such as the ETS family and proteins involved in the apoptotic machinery, such as the 
proapoptotic BIM. Phosphorylation of the predominant form of BIM (BIMEL) by ERK1/2, 
targets it for ubiquitination and proteasomal degradation and may also directly hinder its 
interactions with Bax 14, 15 and selumetinib-induced apoptosis is associated with BIM 
induction.16 
 
Relapsed ALL is generally more drug resistant than newly diagnosed disease and despite the 
use of more intensive chemotherapeutic regimens at ALL relapse, there are lower rates of 
complete remission and end of induction MRD negativity 2, 3. Assessment of in vitro drug 
sensitivity of primary ALL samples have shown that blasts at relapse are significantly more 
resistant to many of the drugs used in upfront treatment protocols, with the highest level of 
drug resistance seen to glucocorticoids (GC)17, 18. GC, such as dexamethasone, are pivotal 
agents in the treatment of all lymphoid malignancies due to their ability to specifically induce 
apoptosis in developing lymphocytes and induction of pro-apoptotic BIM is key to this effect 
19. Thus, BIM is a common effector in both selumetinib and dexamethasone induced 
apoptosis, suggesting the potential for synergy. In addition, GC resistance in ALL has been 
associated with enhanced activation of the pathway and its inhibition has led to GC re-
sensitisation 20-22. These effects may be more pronounced in the context of RAS pathway 
mutated ALL, therefore, we have preclinically evaluated the combination of dexamethasone 
and selumetinib in vitro and in an orthotopic mouse model engrafted with primary-derived 
ALL cells and shown pronounced drug synergism in RAS pathway mutated ALL. These data 
suggest that this drug combination may be highly effective in this significant subgroup of 
patients and has led to the Seludex trial, an international Phase I/II expansion study for the 
treatment of relapsed/refractory RAS pathway mutated ALL. 
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Methods  
Additional methods are found in the supplementary material. 
Compounds and formulation 
Selumetinib was kindly provided by AstraZeneca (Cheshire, UK) and for the in vitro studies, 
was dissolved in DMSO to a concentration of 100mM and stored in single use aliquots at       
-20oC. Dexamethasone was purchased from Sigma-Aldrich (Dorset, UK), dissolved in 
ethanol at 20mM and stored at -20oC. For in vivo studies, selumetinib was prepared as a 
suspension in 0.5% hydroxypropyl methylcellulose + 0.1% polysorbate 80.  
 
Patient Samples 
Primagrafts were generated in NOD SCID γ null (NSG) mice using ALL cells from bone 
marrow samples of children presenting or relapsing with ALL and accessed through the 
Newcastle Haematology Biobank, after appropriate consent (reference numbers 2002/111 and 
07/H0906). Clinical details of the patients are given in Table 1. Mutational screening for RAS 
pathway mutations and assessment of pathway activation by western blotting of p-ERK was 
performed as previously described 8, 23.   
 
In vitro drug sensitivity and synergy 
Freshly harvested primagraft cells were suspended in RPMI1640 with 15% fetal bovine 
serum and plated out in triplicate at a density of 5x105 cells/100μl/well into 96-well plates and 
treated with a range of dexamethasone (0.1nM to 10μM) or selumetinib concentrations (1nM 
to 100μM). After 96 hours, cytotoxicity was assessed using the CellTiter 96 Aqueous One kit 
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(Promega, Southampton, UK). The results were averaged and expressed as a percentage of 
the control vehicle. Survival curves were plotted and growth inhibitory (GI50) values 
calculated using GraphPad Prism software (GraphPad software Inc., San Diego, CA, USA). 
Drug combination experiments were analysed for synergistic, additive, or antagonistic effects 
using the combination index method developed by Chou and Talalay 24. Briefly, primagraft 
cells were treated with fixed dose ratios based on the GI50 values of each drug (x0.25, x0.5, 
x1, x2 and x4) and evaluated by median effect analysis using CalcuSyn software (Cambridge, 
UK). The dose-effect curve for each drug alone is determined using the median-effect 
principle and is compared to the effect achieved with a combination of the two drugs to 
derive a combination index (CI) value.  
 
Pharmacokinetic analyses 
Plasma pharmacokinetics of selumetinib and dexamethasone were determined using non 
compartmental analysis in female CD1 mice after oral dosing. Plasma concentrations of both 
drugs were measured by LCMS (API4000 LCMS/MS, Applied Biosystems, California, 
USA), attached to a Perkin Elmer chromatography system (Perkin Elmer Ltd, Beckonsfield, 
UK) and calibrated using standards prepared in blank mouse plasma. In both cases separation 
was performed using a Gemini 3µ C18 110A column (50x3mm) fitted with a 4x2mm C18 
cartridge (Phenomenex, Macclesfield, UK).  
 
In vivo experiments 
All experiments were performed under the UK home Office NCL- PLL60/4552.  Drug 
efficacy studies were performed as previously described 6. Briefly, primagraft cells were 
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injected intrafemorally and mice were monitored for engraftment every 3-4 weeks by tail 
vein bleed. Blood was red cell lysed and analysed by flow cytometry on a BD FACSCanto II, 
using anti human CD10, CD34 and CD19 and anti-mouse CD45 antibodies. Human 
leukaemia cells were gated and expressed as a % of the total number of nucleated cells. Once 
the level of human leukaemia cells reached >1% of total cells, mice were randomised into 
control vehicle (0.5% hydroxypropyl methylcellulose + 0.1% polysorbate 80) and drug 
treatment groups (6 mice per group) were dosed with dexamethasone, selumetinib or both, by 
oral gavage. Selumetinib was dosed at 25mg/kg BID, while the dexamethasone dosing varied 
in each study. Tumour burden was monitored weekly by flow cytometry. Pharmacodynamic 
studies were performed in highly engrafted mice which were dosed for 72 hours. Spleens 
were removed following euthanasia and assessed by flow cytometry to confirm an 
engraftment of >85%. Cells were lysed and analysed by western blotting for levels of p-ERK, 
ERK2, BIM, MCL1 and α-Tubulin, as described above. 
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Results 
Selumetinib and dexamethasone show synergy in vitro in RAS pathway mutated ALL 
and is associated with enhanced induction of BIM. 
To investigate possible synergism, the R3F9 cell line and primagraft ALL cells, with and 
without Ras pathway mutations (n=8) were treated with dexamethasone, selumetinib and the 
drug combination at 0.25x, 0.5x, 1x, 2x and 4x their respective GI50 concentrations and 
viability data evaluated by median effect analysis. CI for all RAS pathway samples were 
indicative of strong synergy with a mean of 0.1 (range, 0.02-0.15) (Figure 1A, B and 
Supplementary Figure 1). Synergism was not observed in ALL primagraft cells without RAS 
pathway activation, CI >1.2. Mechanistic assessments were performed with GI50 
concentration of both drugs for 24 hours.  As expected, ALL cells treated with selumetinib 
resulted in almost complete inhibition of ERK phosphorylation and downregulation of MCL1 
levels.  Dexamethasone treatment also downregulated pERK levels. Treatment with 
dexamethasone or selumetinib was associated with increased levels of BIM which was 
further enhanced with the drug combination. A representative western blot and a histogram of 
the combined densitometry values (n=4 PDX) are shown in Figures 1C and Supplementary 
Figure 2A. The apoptotic marker, cleaved PARP was enhanced with the drug combination in 
some, but not all PDX samples, at this time point (Supplementary Figure 2B).  While the loss 
in cell viability in non-dividing PDX ALL cells must be due to increased cell death, we also 
showed for the NRAS mutated R3F9 cell line, enhanced apoptosis with the drug combination 
(Supplementary Figures 2 C and D) and BIM knockdown reduced the effect (Supplementary 
Figures  2E and F). There were similar levels of induction of the GR target gene, GILZ in 
both dexamethasone and drug combination treated cells suggesting that enhanced GR 
transcriptional activity is not a component of the synergism (supplementary Figure 3). 
Synergism between selumetinib and other drugs for example, gemcitabine, is highly schedule 
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dependent and sequential rather than simultaneous dosing appears optimal 25. Thus, we 
assessed synergism in primagraft ALL cells dosed simultaneously or with only selumetinib or 
dexamethasone for 24 hours followed by both drugs for an additional 72 hours, prior to cell 
viability assessments. We saw similar synergism across all experimental parameters (Figure 
1D) and thus we selected simultaneous drug administration in subsequent in vivo studies.   
 
Pharmacokinetic studies define clinically relevant oral dose and exclude drug-drug 
interactions 
To determine the optimal oral dose of dexamethasone that will achieve clinically relevant 
serum levels, pharmacokinetic studies were performed in CD1 mice. Mice (n=27) were dosed 
with 0.5, 1 and 5mg/kg dexamethasone by oral gavage and blood samples taken at 15min, 
30min, 1hr, 3hr, 6hr and 24hr and serum dexamethasone levels analysed (Supplementary 
Figure 4A).  A  Tmax of 60 minutes was observed, with Cmax values of 48.9, 94.7 and 766.5 
ng/ml following 0.5, 1 and 5mg/kg doses, respectively. Given the reported Cmax average of 
40-90 ng/ml  in recent UK and American ALL trials, 1mg/kg was deemed the most 
appropriate dose level 26, 27. 
Dexamethasone can induce cytochrome P450 forms, including CYP3A4, the principal 
isoform responsible for selumetinib oxidative metabolism, therefore we performed 
selumetinib pharmacokinetic analyses, alone (25mg/kg) and after co-administration of 
1mg/kg dexamethasone (Supplementary Figures 4B and C). A Tmax of 60 minutes was 
observed, with Cmax values for selumetinib of 4.74ug/ml compared to 5.49 ug/ml, 
respectively (p>0.05, student t test). Other parameters were also similar (Supplementary 
Figure 4C), indicative of no drug-drug interaction (p>0.05 for all).    
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Selumetinib and dexamethasone show synergy in vivo and clear CNS disease 
The drug combination was evaluated in vivo and compared to single drug and control vehicle  
in primagrafts derived from diagnostic ALL (NRAS Q61R and KRAS G12D) and a relapse 
(KRAS G13D).  Scheduling and dosing was by oral gavage and is shown in Figure 2 A-G. 
Due to significant weight loss (>20%) associated with dexamethasone, dosing could not be 
prolonged, even when the dose was lowered from 1mg/kg bid to 0.25mg/kg sid. There was no 
additional toxicity observed in mice given the drug combination. Nevertheless, at the end of 
the dosing period, there was a significant reduction in spleen size with selumetinib and 
dexamethasone alone but was statistically lower in mice given the drug combination, with 
spleen weights approaching those of healthy mice (combined data are shown in Figure 2G) 
(p<0.001).  In addition, brains were assessed for the depth of leukaemia infiltration in the 
leptomeninges. For mice engrafted with L897 and L779 primagraft cells, there was a 
significant reduction in leukaemic infiltration in drug treated mice, with a mean and SD of 
66.3µ+/-100.6 for CV, compared to 3.1µ +/- 12.5 for dexamethasone and 5.37µ +/- 21.475 
for selumetinib (Supplementary Figure 5A). Mice treated with the drug combination showed 
no leukaemic infiltration (p<0.05 for all by student t test). For L779, there was demonstrable 
CNS disease once peripheral ALL exceeded 1% i.e. pre-dosing (Supplementary Figure 5B). 
Clearance of CNS disease in mice engrafted with L829R cells was unevaluable due to 
minimal CNS leukaemia in both CV and drug treated mice. Pharmacodynamic assessment of 
engrafted spleens after short term dosing were consistent with observations in vitro; 
inhibition of ERK phosphorylation and lower MCL1 levels associated with selumetinib 
dosing, similar induction of GILZ with dexamethasone dosing, and modest enhancement of 
BIM levels with the drug combination (Figure 3A-D).  Annexin V binding in circulating ALL 
cells, as detected by multi-parameter flow cytometry, increased in all drug treated mice and 
was highest for the drug combination at both 24 hours and 48 hours (Figure 3E). 
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Discussion 
Selumetinib is a potent, selective, allosteric inhibitor of MEK1/2 with demonstrated anti-
tumour activity and a favourable toxicity profile. It has progressed to phase III clinical trial 
for several types of adult solid cancers 28-30. In the paediatric setting, selumetinib has recently 
undergone phase I clinic testing as a monotherapy in children with BRAF-driven 
recurrent/refractory paediatric low grade glioma which defined a maximum tolerated dose of 
25 mg/m2/dose BID 31. Sustained responses (1 complete, 7 partial) were observed in some 
children and selumetinib was well tolerated, with the most common toxicity being rash. In 
addition, a phase I trial of selumetinib in children with neurofibromatosis type 1 and 
inoperable plexiform neurofibromas, showed partial responses in 17 of 24 children (71%) and 
reported no excess toxicity 32.  
 
While we have previously shown single agent preclinical activity in ALL, selumetinib like 
other MEKi, is likely to show maximal therapeutic benefit in combination. Therefore,  in 
phase III clinical trials for advanced non-small-cell lung cancer and uveal melanoma, 
selumetinib has been evaluated in combination with docetaxel and dacarbazine, respectively 
33. In this current study, we show significant synergy of selumetinib with the synthetic 
glucocorticoid dexamethasone in vitro and in an orthotopic mouse model engrafted with RAS 
pathway activated primary-derived ALL cells. Importantly, we demonstrate this across a 
range of cytogenetic subgroups, including high hyperdiploidy, B-other, t(17;19) and t(1;19). 
Pharmacokinetic data shows clinically relevant drug levels and optimal scheduling and in 
vivo pharmacodynamic analyses confirmed impact on drug targets and apoptosis. 
Mechanistically, the synergism was associated with enhanced induction of the proapoptotic, 
BIM and decreases in the anti-apoptotic BH3 only protein MCL1. BIM is a BH3 only protein 
12 
 
that binds to anti apoptotic BCL2 family members, including MCL1 and BCL2, to liberate 
and directly activate bax and bak which then elicit caspase dependent apoptosis.  BIM is an 
effector protein in both GC and MEK inhibitor response and reducing pERK activity 
enhances BIM levels as well as decreasing MCL1 protein levels by increasing its turnover 34. 
Therefore, we propose that the drug combination enables BIM to more completely inhibit 
anti-apoptotic BH3 only proteins and directly activate BAX and BAK. Others have reported a 
direct effect of MEK inhibition on GR transcriptional activity which may also be contribute 
to the synergism, but this did not appear significant in our experiments at the time point 
chosen22. Epigenetic regulation of the BIM locus due to acetylation has been described in a 
subgroup of GC resistant ALLs and is associated with BIM under expression. Such 
individuals may be expected to have a suboptimal response to the selumetinib/dexamethasone 
drug combination 35. However, the incidence of acetylated BIM in the relapsed setting and in 
the context of RAS pathway mutations has not been described to date. Our synergism data are 
supported by a study from Jones et al., who used an integrated approach to understand GC 
resistance and relapse and identified MAPK pathways as a contributory factor22. In this study, 
knockdown of MEK2 or MEK inhibition enhanced response not only to GC but to other 
chemotherapeutics and was not dependent on the presence of RAS pathway mutations, 
suggestive of activation of the pathway through alternative routes. We have previously shown 
excellent correlation between pERK activation and the presence of RAS pathway mutations, 
although we too noted some rare exceptions which in our study were in part explained by the 
presence of chromosomal translocations, including Ph+ and 11q236.  
 
Drug synergies have also been shown for MEK inhibitors with both traditional 
chemotherapeutics such as gemcitabine and targeted agents including PI3K/AKT inhibitors 
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36, 37 and the BCL-XL inhibitor, Navitoclax (ABT263)38.  Inhibiting the other effector 
pathways of RAS is clearly a rational strategy, however, while we have observed synergism 
of MEK and AKT inhibition in RAS pathway mutated ALL in vitro, the synergism was 
considerably weaker than that observed with dexamethasone (unpublished observations). In 
solid cancers, increased levels of BIM protein are also observed with MEK inhibition, but is 
inactive due to sequestration by high levels of BCL-XL. In the presence of Navitoclax, BIM 
is released, triggering an apoptotic response 38.  
  
We have previously reported a reduction of CNS leukaemia in selumetinib treated mice and 
now confirm this in additional primagraft samples and show complete absence of leukaemic 
infiltrate in the leptomeninges of mice treated with the selumetinib/dexamethasone drug 
combination 6. The identification of CNS disease in mice with similar levels of ALL 
engraftment prior to drug dosing, suggests that the drug combination completely eradicated 
the leukaemia in situ. This is a highly significant finding given the association of RAS 
pathway mutations and CNS disease at relapse that we previously reported in the 
IBFMREZ2002 clinical trial and the fact that in contemporary regimens, the proportion of 
CNS relapses is increasing39. 
 
A key question, relevant to MEKi therapy, is whether Ras pathway mutations are initiating 
events in ALL or secondary, cooperating genetic events and there is evidence for both 
(reviewed in 13).  However, for targeted therapies to be successful, the target is ideally present 
on all tumour cells and we and others have reported that mutations can be subclonal, 
particularly at diagnosis, and can be gained or lost at relapse 6, 40-42.  Importantly, we have 
also shown that mutations at relapse are in the major ALL clone, are often selected from a 
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minor subclone at diagnosis and that apparent ‘loss’ of a Ras pathway mutation can be 
‘replacement’ of one for another 8, 43, 6.   This suggests a dependence on the pathway that can 
be exploited by MEK inhibition and as we show here, is enhanced with dexamethasone co-
exposure. 
 
Based on these promising data, an international  phase I/II clinical trial of oral 
dexamethasone and selumetinib (Seludex) is underway in RAS pathway mutated, multiple 
relapse/refractory ALL. A parallel, national study in adult disease at first relapse is also 
ongoing, since the prevalence of RAS pathway mutations and association with poor 
prognosis has also been noted 44. One relevant observation from selumetinib and other Mek 
inhibitor trials is that the most common toxicity is inflammatory rash. In severe cases, the 
recommended treatment is oral glucocorticoids and no adverse effects of drug co-
administration have been reported 45. Thus, if efficacy is seen in the proposed clinical trials, 
selumetinib and other Mek inhibitors may be a much needed novel therapy for a substantial 
number of children with high risk, relapsed disease. There may also be a role for the drug 
combination in the upfront treatment of RAS-driven, high risk ALL, to avert relapse. 
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Table 1. Clinical features of patients and characterisation of PDX. 
Patient 
ID 
Sex 
Age at 
Diagnosis 
(years) 
Cytogenetics 
 
End of 
Induction MRD 
Ras pathway 
mutation 
 
Clonality 
 
pERK 
L779 M 5.5 
High 
Hyperdiploid 
Intermediate 
NRAS 
(Q61R) 
Clonal Positive 
L897
a
 M 16.8 B other High risk 
KRAS 
(G12D) 
Clonal Positive 
L914 F 7.3 
High 
Hyperdiploid 
Low risk 
CBL/FLT3 
Large 
del/∆836 
Clonal Positive 
L829b 
relapse 
F 3.1 
High 
Hyperdiploid 
High risk 
KRAS 
(G13D) 
Clonal Positive 
L707c F 16.5 t(17;19) High risk 
KRAS 
(insertion) 
Clonal Positive 
LX825 F 14.7 B other High risk Wildtype N/A Negative 
L920 F 4.4 B other Low risk Wildtype N/A Negative 
L848 M 2.5 t(12;21) Low risk Wildtype N/A Negative 
a
patient suffered on-treatment CNS relapse 
bL829 at diagnosis was NRAS G12D 
C patient relapsed with the same KRAS mutation 
B-other group:- 
L897 is negative by FISH for ETV6-RUNX1, BCR-ABL1, MLL and TCF3-PBX1/HLF  
LX825 is negative by FISH for ETV6-RUNX1, BCR-ABL1, MLL, CRLF2, IKZF1, PAX5, IGH 
and  PDGFRB 
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Figure Legends 
Figure 1. Selumetinib and dexamethasone show synergy in vitro in RAS pathway 
mutated ALL and is associated with enhanced levels of BIM 
Viability curves of Ras pathway mutant ALL cells (L829R) with individual drugs and the 
selumetinib/dexamethasone drug combination (A). Histogram of combination indices (CI) for 
the selumetinib/dexamethasone combination in wild type and Ras pathway mutant ALL cells; 
mutated genes are shown in brackets (B). Western analyses of ALL cells (L829R) treated 
with CV or GI50 values of selumetinib (10 µM) and dexamethasone (10 µM), singly and in 
combination (C).  A representative median effect curve (data shown are from L897) after 
simultaneous drug dosing and with each drug added 24 hours prior to the partner drug, 
followed by a further 72 hours incubation (D). 
 
Figure 2. Selumetinib and dexamethasone show synergy in vivo in RAS pathway 
mutated ALL 
In vivo drug efficacy studies of single drug and combination in RAS pathway mutated ALL 
showing dose scheduling and peripheral blood monitoring before and during dosing and 
spleen weights at the end of dosing for L779-NRAS (A and B, respectively),  L897-KRAS (C 
and D) and L829 relapse- KRAS (E and F). For L779, mice were dosed with selumetinib at 
25mg/kg and dex at 1mg/kg twice daily and then once daily after a recovery period. For 
L897, selumetinib was 25mg/kg and dex at 0.5mg/kg (BID), with the dex being increased to 
1mg/kg (SID) following a recovery period and for L829R, selumetinib was dosed at  
25mg/kg (BID) and dex at 0.25mg/kg (SID). Mean and SD are shown for combined spleen 
weight data for all 3 efficacy experiments (G) (One way ANOVA with Tukeys multiple 
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comparison test, ***p <0.001, **** p<0.0001;  n=17 for CV, n=17 for Sel, n=15 for Dex and 
n=14 for Sel and Dex treated mice). 
 
Figure 3. Pharmacodynamic analyses in ALL cells after drug dosing in vivo, supports in 
vitro data. 
Western analyses of spleen cells from mice engrafted with RAS pathway mutant ALL cells 
after 72 hours of dosing (A, L779; NRAS; 25mg/kg selumetinib and 1mg/kg dexamethasone 
bid and B, L897; KRAS; 25mg/kg selumetinib and 0.5mg/kg dexamethasone bid).  
Histograms of densitometry from western analyses, showing mean +/-SEM (3-4 mice per 
treatment) (One way ANOVA with Tukeys multiple comparison test, * p<0.05, **p <0.01, 
(C). Relative expression of GILZ mRNA (mean and SEM) compared to CV as quantified by 
RQPCR expression in all 3 PDX experiments, again after 72 hours dosing (ANOVA as 
before **p<0.01; ns, not significant (D). Histograms of annexin V positive ALL cells (mean 
+/-SEM) determined by flow cytometric analyses of peripheral blood at 24 and 48 hours  
after dosing (2 mice per group)(E). 
22 
 
23 
 
 
 
 
24 
 
 
